The Shareholder Alert today has some interesting d
Post# of 72447
(Total Views: 950)
Posted On: 06/07/2021 5:28:14 PM
The Shareholder Alert today has some interesting direct quotes as well as confirmation of a worldwide need and demand that Brilacidin could fulfill.
From the introductory summary article written by Dr. Liji Thomas from News Medical “With the emergence of new and possibly more pathogenic variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pandemic of coronavirus disease 2019 (COVID-19) may be far from over. And with over 3.7 million deaths recorded since the virus first emerged, the need for effective and safe antivirals has never been greater.”
“SARS-CoV-2 infection is characterized by its unpredictable symptomatology. Asymptomatic in a very large percentage of cases, it causes symptoms in about 15% of cases. Unfortunately, it can induce a raging cytokine storm in about 5% of cases, leaving lung damage and multi-organ dysfunction in its trail as a result of dysregulated systemic inflammation.”
“Among the many drugs that have been deployed for the treatment of COVID-19, none have proved unequivocally effective. Remdesivir is effective only in reducing the duration of hospitalization slightly, but has no impact on mortality. Corticosteroids have potent anti-inflammatory activity, and do reduce the risk of death in severe COVID-19, but are a double-edged weapon.”
The Viruses medical journal has an abundance of key points. I found it interesting that the main scientific authors were from Germany and The Czech Republic. This is a proof point that the international scientific community is becoming aware of Brilacidin. The B-CV19 human trial results will have many various international interested parties anxiously awaiting top line results.
Some interesting quotes from the Viruses medical journal include:
“General antiviral drugs such as remdesivir, lopinavir/ritonavir, and umifenovir are already used, but their effectiveness is limited by the need to treat patients before the peak of viral replication [8,9]. Ribavirin may be favorable as an adjunct therapy but is not effective when administered alone [8,10]. Corticosteroids reduce mortality associated with severe COVID-19 symptoms but increase mortality in patients with coronavirus-associated pneumonia”
“Recently, the defensin-mimetic Brilacidin, a peptidomimetic synthetic small molecule, was shown to inhibit SARS-CoV-2 in a human lung cell line expressing ACE2 by disrupting the virus and blocking entry into cells [22]. Brilacidin together with remdesivir also showed synergistic activity against SARS-CoV-2 in vitro [22].”
2. Conclusions
“Emerging and re-emerging viruses have caused severe socioeconomic disruption over the last two decades, reminding us that we are still unprepared to deal with viral pandemics. This reflects the lack of effective antivirals, removing an essential front line treatment option and making us reliant on vaccination to avoid significant morbidity and mortality. In this opinion article, we have highlighted the potential of AMPs as candidate antiviral drugs or drug leads. AMPs can be produced rapidly by chemical synthesis or the expression of recombinant peptides, and can be modified to improve their efficacy and stability in vivo. AMPs could therefore be used in the fight against COVID-19 and future viral pandemics either as new first-line treatments or as adjuncts to existing antiviral drugs. Given the broad and potent activities of AMPs against multiple viruses, we recommend the funding of research into the development of AMPs as a new therapeutic strategy against viral diseases.”
From the introductory summary article written by Dr. Liji Thomas from News Medical “With the emergence of new and possibly more pathogenic variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pandemic of coronavirus disease 2019 (COVID-19) may be far from over. And with over 3.7 million deaths recorded since the virus first emerged, the need for effective and safe antivirals has never been greater.”
“SARS-CoV-2 infection is characterized by its unpredictable symptomatology. Asymptomatic in a very large percentage of cases, it causes symptoms in about 15% of cases. Unfortunately, it can induce a raging cytokine storm in about 5% of cases, leaving lung damage and multi-organ dysfunction in its trail as a result of dysregulated systemic inflammation.”
“Among the many drugs that have been deployed for the treatment of COVID-19, none have proved unequivocally effective. Remdesivir is effective only in reducing the duration of hospitalization slightly, but has no impact on mortality. Corticosteroids have potent anti-inflammatory activity, and do reduce the risk of death in severe COVID-19, but are a double-edged weapon.”
The Viruses medical journal has an abundance of key points. I found it interesting that the main scientific authors were from Germany and The Czech Republic. This is a proof point that the international scientific community is becoming aware of Brilacidin. The B-CV19 human trial results will have many various international interested parties anxiously awaiting top line results.
Some interesting quotes from the Viruses medical journal include:
“General antiviral drugs such as remdesivir, lopinavir/ritonavir, and umifenovir are already used, but their effectiveness is limited by the need to treat patients before the peak of viral replication [8,9]. Ribavirin may be favorable as an adjunct therapy but is not effective when administered alone [8,10]. Corticosteroids reduce mortality associated with severe COVID-19 symptoms but increase mortality in patients with coronavirus-associated pneumonia”
“Recently, the defensin-mimetic Brilacidin, a peptidomimetic synthetic small molecule, was shown to inhibit SARS-CoV-2 in a human lung cell line expressing ACE2 by disrupting the virus and blocking entry into cells [22]. Brilacidin together with remdesivir also showed synergistic activity against SARS-CoV-2 in vitro [22].”
2. Conclusions
“Emerging and re-emerging viruses have caused severe socioeconomic disruption over the last two decades, reminding us that we are still unprepared to deal with viral pandemics. This reflects the lack of effective antivirals, removing an essential front line treatment option and making us reliant on vaccination to avoid significant morbidity and mortality. In this opinion article, we have highlighted the potential of AMPs as candidate antiviral drugs or drug leads. AMPs can be produced rapidly by chemical synthesis or the expression of recombinant peptides, and can be modified to improve their efficacy and stability in vivo. AMPs could therefore be used in the fight against COVID-19 and future viral pandemics either as new first-line treatments or as adjuncts to existing antiviral drugs. Given the broad and potent activities of AMPs against multiple viruses, we recommend the funding of research into the development of AMPs as a new therapeutic strategy against viral diseases.”
(19)
(0)